Medicine Man Technologies Inc.'s next confirmed earnings release is scheduled for November 18, 2026.
| Earnings Date | 11/18/2026 |
As of December 31, 2023, Medicine Man Technologies Inc. has 74.05M shares outstanding.
| Shares Outstanding | 74.05M |
As of December 31, 2023, Medicine Man Technologies Inc. maintains a current ratio of 0.97, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 160.84, indicating elevated leverage, while an interest coverage ratio of 0.76 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.97 |
| Quick Ratio | 0.43 |
| Debt / Equity | 160.84 |
| Debt / EBITDA | 7.92 |
| Interest Coverage | 0.76 |
Over the twelve months ended December 31, 2023, Medicine Man Technologies Inc. posted a negative return on equity (ROE) of -33.97, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -10.15, reflecting losses generated across the asset base. The company generates approximately 232,958.85 in revenue per employee across its workforce of 740.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.99 indicates how many times Medicine Man Technologies Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | -33.97 |
| Return on Assets (ROA) | -10.15 |
| Revenue Per Employee | 232,958.85 |
| Employee Count | 740.25 |
| Inventory Turnover | 3.99 |
Over the twelve months ended December 31, 2023, Medicine Man Technologies Inc. recorded 19.74M in income tax expense. The company reported a pretax loss of -14.81M and -34.55M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | 19.74M |
As of the close on November 2, 2026, Medicine Man Technologies Inc.'s stock has gained approximately 0.00% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.01.
| 200-Day Moving Average | 0.01 |
Over the twelve months ended December 31, 2023, Medicine Man Technologies Inc. generated 172.45M in revenue and converted that into -34.55M in net income, yielding earnings per share of -0.43. EBITDA reached 24.22M, while operating income came in at 5.09M.
| Revenue | 172.45M |
| Gross Profit | 76.02M |
| Operating Income | 5.09M |
| Pretax Income | -14.81M |
| Net Income | -34.55M |
| EBITDA | 24.22M |
| EBIT | 3.29M |
| Earnings Per Share (EPS) | -0.43 |
As of December 31, 2023, Medicine Man Technologies Inc. holds 19.71M in cash and equivalents against 191.87M in total debt, resulting in a net debt position of 137.56M. Total book value stands at 119.29M, with working capital of -1.79M providing operational flexibility.
| Cash & Cash Equivalents | 19.71M |
| Total Debt | 191.87M |
| Net Debt | 137.56M |
| Equity (Book Value) | 119.29M |
| Book Value Per Share | 1.61 |
| Working Capital | -1.79M |
Medicine Man Technologies Inc. produced 12.20M in operating cash flow over the twelve months ended December 31, 2023. After subtracting -10.62M in capital expenditures, free cash flow totaled 1.59M - equivalent to 0.02 per share.
| Operating Cash Flow | 12.20M |
| Capital Expenditures | -10.62M |
| Free Cash Flow | 1.59M |
| FCF Per Share | 0.02 |
Over the twelve months ended December 31, 2023, Medicine Man Technologies Inc. posted a gross margin of 44.08, reflecting its pricing power and cost economics. The operating margin of 2.95 and net profit margin of -20.03 provide insight into operational efficiency.
| Gross Margin | 44.08 |
| Operating Margin | 2.95 |
| Pretax Margin | -8.59 |
| Profit Margin | -20.03 |
| EBITDA Margin | 14.05 |
These figures cover the twelve months ended December 31, 2023. The dividend payout ratio of 19.10 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.
| Payout Ratio | 19.10 |